Biologic for Bone Disorders and Oncology is under clinical development by Mabwell Shanghai Bioscience and currently in Phase I for Bone Disorders. According to GlobalData, Phase I drugs for Bone Disorders have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Biologic for Bone Disorders and Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Biologic for Bone Disorders and Oncology overview
Biologic is under development for the treatment of bone disorders and cancer.
Mabwell Shanghai Bioscience overview
Mabwell Shanghai Bioscience is a company that is focused on the discovery and industrialization of therapeutic monoclonal antibody, innovative vaccines and long-acting cytokine drugs. The company is headquartered in Shanghai, China.
For a complete picture of Biologic for Bone Disorders and Oncology’s drug-specific PTSR and LoA scores, buy the report here.